Short answer
Monte Rosa Therapeutics, Inc. (GLUE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Monte Rosa Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full results and management commentary available in Exhibit 99.1
- Results release provides the primary update for investors on liquidity, operating expenses and pipeline progress
Item EX-99.1 · Exhibit EX-99.1
- Positive Phase 1 GFORCE-1 results: MRT-8102 achieved 80% to 90% NEK7 degradation with adverse events comparable to placebo
- Three MRT-8102 Phase 2 studies planned: gout in Q4 2026, coronary artery disease and hidradenitis suppurativa in H1 2027
- Novartis Phase 2 starts triggered $87.5 million in milestone payments, including $37.5 million not yet reflected in third-quarter revenue
- Third-quarter collaboration revenue $54.4 million versus $12.8 million, driving net income of $3.1 million versus a $27.1 million loss
- Cash, restricted cash and marketable securities $582.6 million at September 30, expected to fund operations into 2029
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Monte Rosa Therapeutics, Inc. 8-K filings
Get the next GLUE 8-K as it lands
Follow GLUE for push alerts, or ask the research agent what this filing means.